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A hhough popularized only recently, transmyocar- dial laser revascularization (TMR) has a lfistory 
spanning four decades. Sen introduced the concept of 
"myocardial acupuncture" in tile mid-1960s, 1 but it 
was overshadowed by tile remarkable results obtained 
with direct coronary revascularization via coronary 
artery bypass grafting (CABG). Tile use of tile laser for 
this purpose was l,ursued through tile 1980s by Mirho- 
seini and colleagues2; however, it was only in the 1990s, 
with substantial industry support, that sufficient eliui- 
cal experience with TMR was accumulated to generate 
widespread interest and enthusiasm for this therapy, a 4 
Intrigued by reports of what can only be called "dra- 
nmtie" an~na relief obtained with carbon dioxide 
(C02) laser systems in the early 1990s, we initiated our 
involvement with TMR at Waslfington University in 
February 1996. We participated in the phase I trial of 
a new holmium: YAG system (Eclipse Surgical Technol- 
ogies Inc., Sunnyvale, CA) and were the first to use this 
particular energy source clinically for TMR in the 
United States. Our experience was encouraging. The 
results of this and other trials of the CO 2 and holmium: 
YAG systems lead to FDA approval of both types of 
devices for clinical use in the treatment of an~na pec- 
toris and to Medicare reimbursement for the same. As 
such, these devices llave become a part of our arma- 
mentariuln for the management of advanced coronary 
artery disease. However, their place is strictly limited 
in our view and their uhilnate role remains uncertain. 
Theoret ica l  and Phys io lo~c Fomldat ions 
Although a colnplete understanding of mechanisms un- 
derlying the beneficial effects of therapeutic modalities 
is not absolutely necessary, atleast some understanding 
of the theoretical basis is surely desirable. Early in our 
involvement with this tllerapy, Jim Cox, then chief of 
Cardiothoracic Surgery at Washington University, en- 
couraged us to pursue the physiologdc basis for tile 
clinical effects observed. Tile ori~nal concept had been 
the creation of channels through which blood could 
flow analogous to tile extensive sinusoid network oper- 
ative in the reptile heart. However, at tile time of our 
involvement, debate raged over the actual patency of 
the laser channels, as well as the capacity of such 
channels to I)rovide sul)stantial nutritive flow to the 
myocardium. An ahernative mechanism prol)osed was 
tile stimulation of angiogencsis by the laser injury. We 
were struck, however, by the immediacy with which 
patients experienced angina relief. In addition, we were 
unimpressed with tile degree to wllich perfusion was 
augmented. 
Given the apparent disparity between demonstrated 
increased perfilsion and angina relief, as well as tile 
difficulties in explaining a mechanism for increased 
blood flow, we were intrigued by tlle alternative hy- 
pothesis that laser energy denervated tile heart. In our 
laboratories, Dr. King Kwong carried out experiments 
in dogs supporting this llypothcsis. 5,6 Shortly thereaf- 
ter, AI-Sheikh and colleagues, 7 using positron emission 
tomography, demonstrated vidence of sympathetic d - 
nervation in hunmns following TMR supporting this 
hypothesis in tile clinical setting. More recently, the 
resuhs of the animal studies have been called into 
questiona; however, even today tile mechanism of an- 
gina relief remains ubstantially in question. 
Current  Indications 
In the absence of convincing proof of au~nented per- 
filsion, we continue to regard TMR exclusively as symp- 
tomatic treatment for nnreconstructable coronary ar- 
tery disease. We do not believe that the current data 
support its use for tile treatment of "silent iscllemia," 
nor do we advise patients that they can expect o derive 
a survival benefit from tile therapy. During the preop- 
erative interview, we ask tile patient to consider 
whether he or she would want the procedure if all that 
it accomplished was denervation. Ahhough this may 
not be tile mechanism, this concept helps to communi- 
cate what we believe to be tile only proven benefit of tile 
procedure. Whenever conventional bypass grafting is 
possible, we pursue that course, even if coronary end- 
artercctomy will be required. 9 
We do feel that the safety of TMR has been ade- 
quately demonstrated, and we are not reluctant to add 
TMR to conventional bypass grafting if there is an 
ischemic area with inadequate target vessels. Consis- 
tent with our ambivalence about the "revasculariza- 
tion" stimulated or produced by TMR, we have a low 
threslwld to lilace a bypass graft into any vessel, re- 
gardless of its size or quality, in the treatment re ,on.  
Accordingly, in our institution we perform combined 
CABG and TMR more commonly than the "stand 
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alone" procedure. In 2000, for example, at Washington 
University and Barnes-Jewish Hospital, we performed 
30 l)rocedures as a comI)onent of coml)ined therapy 
and 25 as sole therapy. This frequently is done in the 
rcoperative setting. It is not uncommon for us to carry 
out TMR to the inferior and lateral walls and off-pump 
CABG to the circumflex system via the left chest in a 
imtient with a patent internal thoracic artery graft to 
the left anterior descending artery and evidence of 
inferior and lateral ischenfia with a diminutive or dif- 
fusely diseased right system. 
Laser  Dev ice  
We have chosen to use a holmiunl: YAG laser system 
largely for reasons of cost and convenience. The energy 
delivery system uses fiberoptic cables and a nmlleable 
wand that is easy to lnanipulate, making virtually the 
entire free wall of the left ventricle accessible via a 
limited anterior thoracotomy or fldl posterolateral tho- 
raeotomy if eoneonfitant bypass grafting to the circum- 
flex system is planned. 
P reoperat ive  Eva luat io~/D ia~,os t i cs  
All prospcctivc andidates for TMR at our institution 
must have objective evidence of ischemia, preferably 
obtained through thallium 201 imaging. We also insist 
on a coronary angiogram within the preceding six 
months that we ca,, review 1)ersonally for operability. 
Occasionally we opt for aggressive ndartereetomy or
feel that we can bypass to target vessels that may be 
nnappealing but are still graftable. All angiograms are 
reviewed by at least two surgeons to confirm that con- 
ventional grafting cannot be performed. 
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SURGICAL TECHNIQUE 
1 TMR may be performed as a "stand alone" procedure or in combination with conven- 
tional CABG. Either may be performed via a median sternotomy or a thoracotomy ap- 
1,roach, depending on tile territories to be treated. The most frequent indication for the 
comlfined procedure in ou/" practice has been after previous CABG, often in the presence of 
a lmtent internal thoracic artery graft to the left anterior descending artery and with 
occluded vein grafts to the inferior and lateral walls. Occasionally an individual will present 
with lateral wall or lateral and inferior wall isehemia lone, in which cases we have used a 
lateral thoraeotomy approach most often. When a bypass graft must be performed, this 
provides access to the descending thoracic aorta for a proximal anastomosis. When no grafts 
are required, the procedure may be performed via a limited anterior thoraeotomy. 
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When a fldl posterolateral thoracotomy is performed, we enter tile 
fifth intercostal space and "shingle" the sixth rib posteriorly. 
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3 The chest retractor is positioned with tile crossbar anteriorly for 
ultimate attachment of the tissue stabilizer. The inferior pulmonary 
ligament is taken down with eleetrocautery. 






4[ Tile pericardium ay be entered either anterior or posterior to 
the phrenic nerve, or through both routes. This provides easy access 
to virtually tile entire left ventricle. When approaching a circumflex 
marginal vessel for concomitant CABG, we most often start ~th  an 
incision posterior to the phrenic, providing access right down to the 
atrioventricular g oove. 
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5 Stay suturcs ill tile pcricardiunl may be passed through tile subcutancous 
tissue (as shown for clarity) or, more commonly, directly through tile chest 
wall by directing tile tails through a 14-gauge peripheral venous catheter 
inserted at the location of choice and secured in place with snaps. This 
provides maxinmm traction at tile optimal angle while keeping tile strings out 
of tile wound. 
With tile pericardium retracted in this manner, distal vessels are evaluated 
for their adequacy. I f  none are found, then TMR can be carried out at this 
point. I f  a candidate vessel is identified, a partial occlusiou clam I, is placed on 
the descen,ling thoracic aorta for creation of the proximal anastomosis. 
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6 Proximal anastomosis of a vein graft or radial artery to the aorta may be 
performed directly on the aorta if it is of good quality. Frequently, however, 
there will be thickening of the wall or local plaque. This may be overcome by 
creating a larger defect and patching it with a disc of perieardimn (A). The 
proximal anastomosis is then created to this l)atch (B). 
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7 Once the proximal anastomosis has been completed, a tissue stabilizer is 
positioned appropriately. 
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8 Tile distal anastomosis i carried out in tile usual manner, with 
control achieved proximally or both proximally and distally using elastic 
tapes. 
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9 After tile bypass graft is completed, tile inferior and lateral 
walls may be accessed by elevating the apex of the heart. 
Channels are created at approximately one-era intervals be~n- 
ning at tile base and moving toward the apex. Most often, four 
or five channels may be made in rapid succession, ttemostasis  
then achieved by providing digital pressure or by applying a 
sponge over the entire treatment area. 




l 0  If tile anterior wall requires treatment, hen it is easily accessed by 
depressing the apex. 
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11 If stand-alone TMR is planned, access call be achieved via a small anterior 
thoraeotomy ill the fifth intercostal SlmCe. The pericardium is then opened anterior to the 
phrenie nerve. Access to the base of tile heart is limited, lint tile inferior, lateral, and 
anterior walls can be accessed simply by deflecting tile ventricle as needed. The malleable 
TMR wand can be shaped as needed to access all portions of the ventricle. 
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Postoperat ive Care 
The most important aspect of postoperative care is to 
treat tile patient under the presmfiption that there has 
been no improvement in perfusion. Accordingly, we 
caution the house staff and nursing staff to take all 
patient complaints of chest pain seriously. Such com- 
plaints are assumed to represent an~na--not incisional 
pain~unti l  proven otherwise. Thoracic epidural cath- 
eters are placed in the operating room for postopera- 
tive Imin control, and lmtient-controlled analgesia is 
initiated when these catheters are removed. We also 
insist that all preoperative antianginal medications be 
resumed as close to the preoperative dose as the pa- 
tient's hemodynamics pernfit. Nitroglycerine and lido- 
caine are initiated in the operating room before begin- 
ning therapy and are continued postoperatively for 12 
to 18 hours. 
Follow-Up 
We expect all patients to be discharged on their full 
preoperative medical re ,men and, presuming (hoping) 
that an~ogenesis plays some role in TMR, we make no 
attempt to reduce that re ,men in the first three to six 
months. In most instances, patients are pleased simply 
to have an improvement in symptoms even if they 
continue to take a complex medical re,men.  Postoper- 
ative thallium studies are performed six months post- 
operatively as an indicator of residual isehemia. Tile 
weaning of antian~nal medications i then left to the 
discretion of the referring eardiol%dst, with symptoms 
and the postoperative p rfilsion study as a guide. 
Expected Long-Term Res~dts and the Ult imate 
Place of  TMR 
As an indirect mode of revascularization, TMR is un- 
likely to unseat direct modalities uch as CABG or 
an~oplasty. Economic arguments for its use are dimin- 
ished by the current capabilities for CABG without 
cardiopuhnonary b pass. The clinical resuhs of TMR 
remain mixed. An~na relief is reprodncible in ahnost 
all series, however, the resuhs of perfitsion stndies, 
exercise tolerance tests, assessments of ventricular 
function, anti even late survival are conflicting. An 
exhaustive review of this subject is beyond our scope. 
Nonetheless, it is clear that, in the absence of a clear 
physiolo~c foundation for this therapy, the long-term 
future of TMR is at best uncertain. If it is true that the 
delivery of injury to the tissues via laser energy stimu- 
lates an~ogenesis, then it is likely that more precise 
modalities for achieving this effect xcill be developed 
(e.g., administration f specific growth factors). Still, in 
the absence of these alternatives. TMR remains auseful 
adjunct for the treatment of selected ischemic territo- 
ries. In the short run, given the ease with which the 
procedure can be performed and its apparent safety, 
the challenge will be resistance to its overuse. 
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